Upregulation of the tissue inhibitor of metalloproteinase-1 protein is associated with progression of human non-small-cell lung cancer

Journal of Clinical Oncology

Volumn 22, Issue 16, 2004, Pages 3218-3229

  Aljada, Ibrahim S ^a   Ramnath, Nithya ^a   Donohue, Kathleen ^a   Harvey, Shashi ^a   Brooks, John J ^a   Wiseman, Sam M ^a   Khoury, Thaer ^a   Loewen, Gregory ^a   Slocum, Harry K ^a   Anderson, Timothy M ^a   Bepler, Gerold ^a   Tan, Dongfeng ^a  

^a UNIVERSITY AT BUFFALO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GELATINASE A; GELATINASE B; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TUMOR MARKER;

AGE DISTRIBUTION; ARTICLE; CANCER GROWTH; CANCER STAGING; CANCER SURVIVAL; COMPARATIVE STUDY; CONFIDENCE INTERVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ASSOCIATION; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; MULTIVARIATE ANALYSIS; OUTCOMES RESEARCH; PHYSICAL PERFORMANCE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; RISK ASSESSMENT; STATISTICAL SIGNIFICANCE; UPREGULATION; ADULT; AGED; BIOSYNTHESIS; DISEASE COURSE; FEMALE; LUNG TUMOR; MALE; MIDDLE AGED; PATHOLOGY; RETROSPECTIVE STUDY; SURVIVAL;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE PROGRESSION; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION;

EID: 4344637105     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2004.02.110     Document Type: Article

References (65)

1. Greenlee RT, Hill-Harmon BB, Murray T, et al: Cancer statistics, 2001. CA Cancer J Clin, 51:16-36, 2001
2. Cho NH, Hong KP, Hong SH, et al: MMP expression profiling in recurred stage IB lung cancer. Oncogene 23:845-851, 2004
3. Egeblad M, Werb Z: New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2:161-173, 2002
4. Nelson AR, Fingleton B, Rothenberg ML, et al: Matrix metalloproteinases: Biologic activity and clinical implications. J Clin Oncol 18:1135-1149, 2000
5. Stetler-Stevenson WG: Matrix metalloproteinases in angiogenesis: A moving target for therapeutic intervention. J Clin Invest 103:1237-1244, 1999
6. Deryugina El, Soroceanu L, Strongin AY: Up-regulation of vascular endothelial growth factor by membrane-type 1 matrix metalloproteinase stimulates human glioma xenograft growth and angiogenesis. Cancer Res 62:580-588, 2002
7. Denhardt DT, Feng B, Edwards DR, et al: Tissue inhibitor of metalloproteinase (TIMP, aka EPA): Structure, control of expression and biological functions. Pharmacol Ther 59:329-336, 1993
8. Uria JA, Ferrand AA, Velasco G, et al: Structure and expression in breast tumors of human TIMP-3, a new member of the metalloproteinase inhibitor family. Cancer Res 54:2091-2096, 1994
9. Jiang Y, Goldberg ID, Shi YE: Complex roles of tissue inhibitors of metalloproteinases in cancer. Oncogene 21:2245-2252, 2002
10. Coussens LM, Fingleton B, Matrisian LM: Matrix metalloproteinase inhibitors and cancer: Trials and tribulations. Science 295:2387-2392, 2002
11. Stetler-Stevenson WG, Gersch N, Golde DW: Tissue inhibitor of metalloproteinase-2 (TIMP2) has erythroid-potentiating activity. FEBS Lett 296:231-234, 1992
12. Hayakawa T, Yamashita K, Tanzanwa K, et al: Growth- promoting activity of tissue inhibitor of metalloproteinases-I (TIMP-I) for a wide range cells. FEBS Lett 298:29-32, 1992
13. Li GY, Fridman R, Kim HR: Tissue inhibitor of metalloproteinase-1 inhibits apoptosis of human breast epithelial cells. Cancer Res 59:6267-6275, 1999
14. Guedez L, Stetler-Stevenson WG, Wolff L, et al: In vitro suppression of programmed cell death of B cells by tissue inhibitor of metalloproteinases-1. J Clin Invest 102:2002-2010, 1998
15. Zeng ZS, Cohen AM, Zhang ZF, et al: Elevated tissue inhibitor of metalloproteinase 1 RNA in colorectal cancer stroma correlates with lymph node and distant metastases. Clin Cancer Res 1:899-906, 1995
16. Fong KM, Kida Y, Zimmerman PV, et al: TIMP-1 and adverse prognosis in non-small cell lung cancer. Clin Cancer Res 2:1369-1372, 1996
17. Wang Z, Juttermann R, Soloway PD: TIMP-2 is required for efficient activation of proMMP-2 in vivo. J Biol Chem 275:26411-26415, 2000
18. Travis WD, Colby TV, Corrin B, et al: World Health Organization Classification of Lung and Pleural Tumors. Berlin, Germany, Springer- Verlag, 1999
19. Mountain C: Revisions in the international system for staging lung cancer. Chest 111:1710-1717, 1997
20. Ramnath N, Hernandez F, Tan DF, et al: Mcm-2 is an independent predictor of survival in patients with non-small cell lung cancer. J Clin Oncol 19:4259-4266, 2001
21. Tan D, Li Q, Ramnath N, et al: Prognostic relevance of the expression of p53 oncoprotein in non-small cell lung cancer. Anticancer Res 23:1665-1672, 2003
22. Tan D, Kirley S, Li Q, et al: Loss of Cables protein expression in human non-small cell lung cancer: A tissue microarray study. Hum Pathol 34:143-149, 2003
23. Harvey SR, Hurd TC, Markus G, et al: Evaluation of urinary plasminogen activator, its receptor, matrix metalloproteinase-9, and von Willebrand factor in pancreatic cancer. Clin Cancer Res 9:4935-4943, 2003
24. Agresti A: Categorical Data Analysis. New York, NY, John Wiley & Sons, 1990, pp 306-347
25. Kumaki F, Matshi K, Kawai T, et al: Expression of matrix metalloproteinases in invasive pulmonary adenocarcinoma with bronchioloalveolar component and atypical adenomatous hyperplasia. Am J Pathol 159:2125-2135, 2001
26. Suzuki M, Lizasa T, Fujisawa T, et al: Expression of matrix metalloproteinases and tissue inhibitor of matrix metalloproteinase in non-small cell lung cancer. Invasion Metastasis 18:134-141, 1998
27. Kitamura H, Oosawa Y, Kawano N, et al: Basement membrane patterns, gelatinase A and tissue inhibitor of metalloproteinase-2 expressions, and stromal fibrosis during the development of peripheral lung adenocarcinoma. Hum Pathol 30:331-338, 1999
28. Kawano N, Osawa H, Ito T, et al: Expression of gelatinase A, tissue inhibitor of metalloproteinase-2, matrilysin, and trypsin (ogen) in lung neoplasms: An immunohistochemical study. Hum Pathol 28:613-622, 1997
29. Martin B, Paesmans M, Berghmans T, et al: Role of Bcl-2 as a prognostic factor for survival in lung cancer: A systematic review of the literature with meta-analysis. Br J Cancer 89:55-64, 2003
30. McCarthy K, Maguire T, McGreal G, et al: High levels of tissue inhibitor of metalloproteinase-1 predict poor outcome in patients with breast cancer. Int J Cancer 84:4448, 1999
31. Thomas P, Khokha R, Shepherd F, et al: Differential expression of matrix metalloproteinases and their inhibitors in non-small cell lung cancer. J Pathol 190:150-156, 2000
32. Nakada M, Kita D, Futami K, et al: Roles of membrane type 1 matrix metalloproteinase and tissue inhibitor of metalloproteinase 2 in invasion and dissemination of human malignant glioma. J Neurosurg 94:464-473, 2001
33. Urbanski SJ, Edwards DR, Mailand A, et al: Expression of metalloproteinases and their inhibitors in primary pulmonary carcinomas. Br J Cancer 66:1188-1194, 1992
34. Nakagawa H, Yagihashi S: Expression of type IV collagen and its degrading enzymes in squamous cell carcinoma of lung. Jpn J Cancer Res 85:934-938, 1994
35. Kallakury BV, Karikehalli S, Haholu A, et al: Increased expression of matrix metalloproteinases 2 and 9 and tissue inhibitors of metalloproteinase 1 and 2 correlate with poor prognosis variables in renal cell carcinoma. Clin Cancer Res 7:3113-3119, 2001
36. Trudel D, Fradet Y, Meyer F, et al: Significance of MMP-2 expression in prostate cancer: An immunohistochemical study. Cancer Res 63:8511-8515, 2003
37. Manenti L, Paganoni P, Floriani I, et al: Expression levels of vascular endothelial growth factor, matrix metalloproteinases 2 and 9 and tissue inhibitor of metalloproteinases 1 and 2 in the plasma of patients with ovarian carcinoma. Eur J Cancer 39:1948-1956, 2003
38. Bremnes RM, Veve R, Gabrielson E, et al: High-throughput tissue microassay analysis used to evaluate biology and prognostic significance of the e-cadherin pathway in non-small-cell lung cancer. J Clin Oncol 20:2417-2428, 2002
39. Onn A, Correa AM, Gilcrease M, et al: Synchronous overexpression of epidermal growth factor receptor and HER2-neu protein is a predictor of poor outcome in patients with stage I non-small cell lung cancer. Clin Cancer Res 10:136-143, 2004 (1 pt 1)
40. Ylisirnio S, Hoyhtya M, Makitaro R, et al: Elevated serum levels of type I collagen degradation marker ICTP and tissue inhibitor of metalloproteinase (TIMP) 1 are associated with poor prognosis in lung cancer. Clin Cancer Res 7:1633-1637, 2001
41. Still K, Robson CN, Autzen P, et al: Localization and quantification of mRNA for matrix metalloproteinase-2 (MMP-2) and tissue inhibitor of matrix metalloproteinase-2 (TIMP-2) in human benign and malignant prostatic tissue. Prostate 42:18-25, 2000
42. Yano A, Nakamoto T, Mashimoto K, et al: Localization and expression of tissue inhibitor of metalloproteinase-1 in human urothelial cancer. J Urol 167:729-734, 2002
43. Shofuda K, Moriyama K, Nishihashi A, et al: Role of tissue inhibitor of metalloproteinases-2 (TIMP-2) in regulation of pro-gelatinase A activation catalyzed by membrane-type matrix metalloproteinase-1 (MT1-MMP) in human cancer cells. J Biochem 124:462-470, 1998
44. Butler GS, Butler MJ, Atkinson SJ, et al: The TIMP2 membrane type 1 metalloproteinase "receptor" regulates the concentration and efficient activation of progelatinase A: A kinetic study. J Biol Chem 273:871-880, 1998
45. Luparello C, Avanzato G, Carella C, et al: Tissue inhibitor of metalloprotease (TIMP)-1 and proliferative behavior of clonal breast cancer cells. Breast Cancer Res Treat 54:235-244, 1999
46. Hayakawa T, Yamashita K, Ohuchi E, et al: Cell growth-promoting activity of tissue inhibitor of metalloproteinases-2 (TIMP-2). J Cell Sci 107:2373-2379, 1994 (pt 9)
47. Laack E, Nikbakht H, Peters A, et al: Expression of CEACAM1 in adenocarcinoma of the lung: A factor of independent prognostic significance. J Clin Oncol 20:4279-4284, 2002
48. Koutsami MK, Gorgoulis VG, Kastrinakis NG, et al: Prognostic factors in non-small cell lung cancer. Anticancer Res 22:347-374, 2002
49. Yoshida T, Tanaka S, Mogi A, et al: The clinical significance of cyclin B1 and Wee1 expression in non-small-cell lung cancer. Ann Oncol 15:252-256, 2004
50. Gessner C, Woischwill C, Schumacher A, et al: Nuclear YB-1 expression as a negative prognostic marker in non-small cell lung cancer. Eur Respir J 23:14-19, 2004
51. Chandrachud LM, Pendleton N, Chishoim DM, et al: Relationship between vascularity, age and survival in non-small cell lung cancer. Br J Cancer 76:1367-1375. 1997
52. Strauss GM, Kwiatkowski DJ, Harpole DH, et al: Molecular and pathologic markers in stage I non-small cell carcinoma of the lung. J Clin Oncol 13:1265-1279, 1995
53. Bepler G, Gautam A, McIntyre LM, et al: Prognostic significance of molecular genetic aberrations on chromosome segment 11p15.5 in non-small-cell lung cancer. J Clin Oncol 20:1353-1360, 2002
54. Jiang Y, Wang M, Celiker MY, et al: Stimulation of mammary tumorigenesis by systemic tissue inhibitor of matrix metalloproteinase 4 gene delivery. Cancer Res 61:2365-2370, 2001
55. Liotta LA, Kohn EC, Petricoin EF: Clinical proteomics: Personalized molecular medicine. JAMA 286:2211-2214, 2001
56. Soloway P, Alexander CM, Werb Z, et al: Targeted mutagenesis of Timp-1 reveals that lung tumor invasion is influenced by Timp-1 genotype but not by that of the host. Oncogene 13:2307-2314, 1996
57. Levitt NC, Eskens FALM, O'Byrne KJ, et al: Phase I and pharmacological study of the oral matrix metalloproteinase inhibitor, MMI270 (CGS27023A), in patients with advanced solid cancer. Clin Cancer Res 7:1912-1922, 2001
58. Macaulay VM, O'Byrne KJ, Sanders MP, et al: Phase I study of intrapleural batimastat(BB-94), a matrix metalloproteinase inhibitor, in the treatment of malignant pleural effusions. Clin Cancer Res 5:513-520, 1999
59. Kruger A, Soeltl R, Sopov I, et al: Hydroxamate-type matrix metalloproteinase inhibitor batimastat promotes liver metastasis. Cancer Res 61:1272-1275, 2001
60. Patterson BC, Sang QA: Angiostatin-converting enzyme activities of human matrilysin (MMP-7) and gelatinase B/type IV collagenase (MMP-9). J Biol Chem 272:28823-28825, 1997
61. Pozzi A, Moberg PE, Miles LA, et al: Elevated matrix metalloprotease and angiostatin levels in integrin alpha 1 knockout mice cause reduced tumor vascularization. Proc Natl Acad Sci U S A 97:2202-2207, 2000
62. Bosken CH, Wei Q, Amos CI, et al: An analysis of DNA repair as a determinant of survival in patients with non-small cell lung cancer. J Natl Cancer Inst 94:1091-1099, 2002
63. Nicholson SA, Okby NT, Khan MA, et al: Alterations of p14ARF, p53, and p73 genes involved in the E2F-1-mediated apoptotic pathways in non-small cell lung carcinoma. Cancer Res 61:5636-5643, 2001
64. Beer DG, Kardia SL, Huang CC, et al: Gene-expression profiles predict survival of patients with lung adenocarcinoma. Nat Med 8:816-824, 2002
65. Zochbauer-Muller S, Fong KM, Virmani AK, et al: Aberrant promoter methylation of multiple genes in non-small cell lung cancers. Cancer Res 61:249-255, 2001